Aquestive Therapeutics initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Raghuram Selvaraju started Aquestive Therapeutics with a Buy rating and $10 price target. Aquestive is an emerging specialty pharma company optimizing the delivery of existing, well-known medications, says the analyst.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.